Aspartylphenylalanine

Introduction

Background

Aspartylphenylalanine is a dipeptide formed from the amino acids aspartic acid and phenylalanine. It occurs naturally as a product of protein breakdown in the body. It is also notably a key component and metabolic product of aspartame, an artificial sweetener, where it is found as aspartyl-phenylalanine methyl ester.

Biological Basis

Upon ingestion, aspartylphenylalanine is typically hydrolyzed, or broken down, into its two constituent amino acids: aspartic acid and phenylalanine. These amino acids then enter the body’s normal metabolic pathways. Phenylalanine, an essential amino acid, undergoes various metabolic processes, including its conversion to tyrosine. Genetic variations can significantly influence the efficiency of these metabolic pathways, thereby affecting the concentrations and interconversion of amino acids within the serum.^[1]For example, genome-wide association studies have identified single nucleotide polymorphisms (SNPs) associated with specific metabolite profiles, including amino acids, in human serum. One such study revealed that a polymorphism in the_PARK2_ gene, rs992037 , alters the concentrations of several amino acids, suggesting an impact on amino acid interconversion pathways.^[1]

Clinical Relevance

The metabolism of phenylalanine is of significant clinical importance due to the inherited metabolic disorder phenylketonuria (PKU). Individuals with PKU lack or have a deficient phenylalanine hydroxylase enzyme, which is crucial for metabolizing phenylalanine. This deficiency leads to a toxic accumulation of phenylalanine in the body, which can cause severe neurological damage if not managed through a strict low-phenylalanine diet. Given that aspartylphenylalanine is a source of phenylalanine (especially from aspartame), its metabolism is a critical consideration for individuals living with PKU. Research indicates that genetic variants can impact diverse metabolic pathways, including those involving amino acids, which has broader implications for human health.^[1]

Social Importance

Aspartylphenylalanine carries social importance primarily through its connection to aspartame, a widely used artificial sweetener in numerous food and beverage products. The extensive use of aspartame has led to public discussions and debates concerning its safety and potential health effects, particularly for sensitive populations like those with PKU, who must meticulously control their phenylalanine intake. A deeper understanding of the genetic factors that influence amino acid metabolism, including those related to aspartylphenylalanine, is vital for developing personalized dietary recommendations and informing public health guidelines. Studies exploring the genetic underpinnings of metabolite profiles, including amino acids, contribute to our comprehension of the intricate relationship between genetics, diet, and health outcomes.^[1]

Limitations

Methodological and Statistical Constraints

The study of aspartylphenylalanine may encounter limitations related to statistical power and study design inherent in genome-wide association studies (GWAS). Due to moderate sample sizes and the stringent significance thresholds required to correct for extensive multiple testing, there is a limited power to detect genetic variants with modest effects on aspartylphenylalanine levels. This constraint increases the likelihood of false-negative findings, potentially overlooking true associations that do not reach genome-wide significance.^[2]

While GWAS are valuable for unbiased gene discovery, their reliance on a subset of all available single nucleotide polymorphisms (SNPs) can lead to incomplete genomic coverage, potentially missing causal variants or entire genes that influence aspartylphenylalanine. Furthermore, the quality of imputation, especially for less common variants or those not well-represented in reference panels, can impact the discovery of associations. Such limitations can also complicate replication efforts, as different studies might identify distinct SNPs in linkage disequilibrium with an unknown causal variant, leading to apparent non-replication at the SNP level.^[3]

The interpretation of effect sizes and the proportion of variance explained for aspartylphenylalanine should be approached with caution when estimates are derived from the mean of multiple observations, such as repeated measures within individuals or observations from monozygotic twin pairs. These estimates may not directly reflect the true population-level effects without appropriate adjustments. Additionally, the challenge of replicating previously reported associations is a notable limitation, often stemming from differences in study design, statistical power, or the specific genetic variants interrogated across diverse cohorts.^[4]

Generalizability and Population Specificity

A significant limitation for understanding the genetics of aspartylphenylalanine is the predominantly European ancestry of the study cohorts. Findings from populations primarily composed of individuals of white European descent may not be directly generalizable to other ethnic or racial groups, as genetic architecture, allele frequencies, and linkage disequilibrium patterns can vary considerably across diverse populations. This limits the broader applicability of the identified genetic associations for aspartylphenylalanine and underscores the need for studies in more diverse populations.^[5]

Moreover, specific characteristics of the cohorts, such as a focus on middle-aged to elderly participants or the collection of genetic material at later examination points, could introduce biases like survival bias. Such biases might skew the observed genetic associations for aspartylphenylalanine, making it challenging to extrapolate findings to younger populations or individuals with different health trajectories. Efforts to control for population stratification within seemingly homogeneous groups, while crucial, also highlight the underlying genetic complexities that can affect generalizability.^[5]

Environmental Influences and Unexplained Variation

The genetic influence on aspartylphenylalanine levels may be context-specific, meaning that the effects of certain genetic variants could be modulated by environmental factors, lifestyle choices, or other physiological conditions. Many studies, however, do not comprehensively investigate these complex gene-environment interactions. This omission can lead to an incomplete understanding of the genetic contributions to aspartylphenylalanine, potentially underestimating the full impact of genetic factors or misinterpreting their direct effects in the absence of environmental context.^[2]

Despite identifying significant genetic associations, these variants often explain only a fraction of the total phenotypic variance for aspartylphenylalanine, pointing to substantial “missing heritability.” This suggests that other genetic factors, such as rare variants, structural genomic variations, or epigenetic modifications, along with unmeasured environmental influences and intricate gene-environment interplay, contribute significantly to the trait. A more comprehensive understanding of aspartylphenylalanine will require further research into these uncharacterized genetic and environmental components.

Variants

The genetic variations within genes like ACE and ABOplay significant roles in determining individual physiological characteristics, influencing everything from blood pressure regulation to blood group type and metabolic profiles. These variants, including specific single nucleotide polymorphisms (SNPs) such asrs4363 , rs4351 , rs4329 in ACE and rs992108547 in ABO, contribute to the intricate network of human genetic diversity and its impact on health. Understanding these genetic differences provides insight into disease susceptibility and metabolic responses, including potential indirect implications for the processing of dietary components like aspartylphenylalanine.

The ACE(Angiotensin-Converting Enzyme) gene encodes an enzyme crucial for the body’s renin-angiotensin-aldosterone system (RAAS), a key regulator of blood pressure and fluid balance.ACE converts angiotensin I to angiotensin II, a powerful vasoconstrictor, and also inactivates bradykinin, a vasodilator. Variants in the ACE gene, such as rs4363 , rs4351 , and rs4329 , can influence the efficiency of this enzyme, thereby affecting circulating levels of these critical peptides. While the specific functional consequences of these individual SNPs are complex, ACEgene variations are broadly associated with individual differences in blood pressure, risk for cardiovascular diseases, and the efficacy of ACE inhibitor medications.^[6] The broader metabolic context for these ACEvariants, particularly in relation to overlapping traits like cardiovascular health and lipid levels, suggests a potential indirect influence on overall metabolic homeostasis, which could broadly affect the processing and utilization of various dietary compounds, including dipeptides like aspartylphenylalanine.

The ABO gene is renowned for determining the major human blood groups (A, B, and O) by encoding glycosyltransferase enzymes that add specific sugar residues to cell surface antigens. For instance, the O blood group arises from a genetic variant (rs8176719 ) characterized by a G deletion, which leads to a premature termination codon and an inactive enzyme. ^[6] This gene exhibits remarkable allelic variation, with different alleles encoding enzymes that possess distinct specificities and activities. ^[7] The specific variant rs992108547 within the ABO gene, like other ABO SNPs, can contribute to these variations in enzyme function and antigen expression. Beyond its role in blood typing, ABOgene variants have been consistently linked to a range of health outcomes, including the risk of cardiovascular disease, susceptibility to certain infections, and influencing levels of circulating biomarkers such as TNF-alpha.^[6] The broad influence of ABOon systemic factors and metabolite profiles suggests that its variants could indirectly impact general metabolic pathways, potentially affecting how the body processes diverse molecules, including dipeptides like aspartylphenylalanine, through altered inflammatory or metabolic states.

Key Variants

RS ID	Gene	Related Traits
rs4363 rs4351 rs4329	ACE	angiotensin-converting enzyme measurement HWESASLLR measurement level of Isoleucyl-Threonine in blood X-14189—leucylalanine measurement X-14208—phenylalanylserine measurement
rs992108547	ABO	level of Sterol ester (27:1/18:0) in blood serum E-selectin amount X-14189—leucylalanine measurement aspartylphenylalanine measurement

Classification, Definition, and Terminology

Definition and Operational Measurement

Aspartate aminotransferase (AST) is an enzyme that serves as a crucial biomarker for metabolic health, particularly in assessing liver function.^[5]This enzyme, also historically known as serum glutamic oxaloacetic transaminase (SGOT), plays a vital role in amino acid metabolism by facilitating the transfer of an amino group from aspartate to α-ketoglutarate.^[8]Its presence and activity are widespread, being found in various tissues including the liver, heart, and skeletal muscle.^[8]As a trait, AST levels in serum reflect physiological status, making it a key focus in studies investigating metabolic profiles and disease associations.^[1]

Operational definitions for AST involve its quantitative measurement in biological samples, primarily serum. ^[5] The concentration or activity of AST is typically determined using enzymatic methods, such as the kinetic method, which can be performed with specific reagent kits like the Beckman Liquid-Stat Reagent Kit. ^[5] To ensure accuracy and comparability across studies, blood samples are often collected after an overnight fast, and results are reported using standardized SI units. ^[9] These rigorous measurement approaches are critical for consistent data generation in large-scale research, including genome-wide association studies. ^[9]

Classification Systems and Clinical Significance

AST is broadly classified as a liver enzyme, often examined in conjunction with other liver function markers such as alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), and alkaline phosphatase (ALP).^[8] Within clinical classification systems, elevated AST levels can indicate hepatocellular damage, making it a valuable diagnostic criterion for liver diseases. However, its presence in other tissues necessitates a broader interpretation, often requiring correlation with other biomarkers for precise diagnosis. ^[8] In research, AST is categorized as a “biomarker trait” or “metabolic trait” due to its utility in reflecting underlying metabolic processes and its association with genetic variations. ^[5]

The assessment of AST often employs both categorical and dimensional approaches. While specific thresholds and cut-off values are used clinically to categorize levels as normal or elevated, research studies frequently treat AST as a continuous quantitative trait. ^[5] This dimensional approach allows for detailed statistical analysis, particularly in genome-wide association studies, to identify genetic loci that influence its plasma levels and potentially contribute to conditions like dyslipidemia or metabolic syndrome. ^[9] Understanding these genetic influences provides insights into biological pathways and potential therapeutic targets. ^[9]

Terminology and Nomenclature

The primary and most widely accepted terminology for this enzyme is Aspartate Aminotransferase, commonly abbreviated as AST.^[8] An older, less frequently used synonym is Serum Glutamic Oxaloacetic Transaminase (SGOT). The standardized nomenclature of AST ensures clarity and consistency in communication across clinical, research, and public health domains. ^[8] In the context of large-scale genetic and metabolic research, AST is often referred to as a “biomarker trait” or a “metabolic trait,” highlighting its role as a measurable characteristic that can be linked to genetic factors. ^[5]

Related concepts frequently encountered alongside AST include its counterparts in liver function panels, such as ALT, GGT, and ALP, which provide a more comprehensive picture of hepatic health. ^[8]The study of AST falls within the broader field of metabolomics, which involves the comprehensive analysis of metabolite profiles in biological systems.^[1] Standardized vocabularies are crucial for integrating data from diverse studies, such as those involving metabolic traits and genetic variations, thereby enhancing the collective understanding of complex biological systems. ^[1]

Biological Background for Aspartylphenylalanine

Amino Acid Homeostasis and Metabolic Interconversion

Amino acids are fundamental building blocks of proteins and vital metabolites within the human body, playing crucial roles in various physiological processes. The precise balance, or homeostasis, of these compounds is critical for cellular function and overall health. Genetic variations can significantly influence the steady-state concentrations of key amino acids, impacting their availability for synthesis pathways or their accumulation due to impaired degradation. These variations can modulate metabolic pathways that involve the interconversion of different amino acids, ensuring the body’s adaptive capacity to changing metabolic demands. ^[1]For instance, specific genetic polymorphisms have been observed to affect metabolic pathways that process glutamate and other amino acids, highlighting the interconnectedness of these biochemical routes.^[1]

Genetic Regulation of Amino Acid Pathways

Genetic mechanisms play a central role in controlling amino acid metabolism. Genes encode the enzymes and regulatory proteins that orchestrate the synthesis, breakdown, and modification of amino acids. A notable example is thePARK2 gene, which codes for parkin, a type of ubiquitin ligase. ^[1] Polymorphisms within genes like PARK2 can alter the efficiency of metabolic reactions, leading to changes in the concentrations of specific amino acids or their derivatives. ^[1]Such genetic variations can result in a distinct “metabolic footprint,” where the patterns of metabolite concentrations reflect the impact of the genetic variant on a particular metabolic pathway, such as amino acid interconversion.^[1]

Cellular Degradation and Amino Acid Recycling

The functional role of ubiquitin ligases, like the protein encoded by PARK2, is fundamental to cellular protein degradation. Ubiquitin ligases mark specific proteins for destruction via the ubiquitin-proteasome system, a critical pathway for removing damaged or unnecessary proteins and regulating cellular processes. ^[1]This degradation process is essential for recycling amino acids, making them available for the synthesis of new proteins or for energy production. Disruptions in these degradation pathways, potentially influenced by genetic variants, can alter the overall balance of amino acid pools and impact the efficiency of amino acid interconversion within cells.^[1]

Pathways and Mechanisms

Metabolic Regulation and Flux Control

Biological systems maintain homeostasis through intricate metabolic networks that govern energy production, biosynthesis, and catabolism. A key example is the mevalonate pathway, regulated by HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), which is essential for cholesterol and isoprenoid biosynthesis. ^[10] Genetic variants, such as common SNPs in HMGCR, can influence this pathway by affecting the alternative splicing of exon 13, thereby impacting LDL-cholesterol levels. ^[11] Similarly, the FADS1 gene, part of the FADS1/FADS2cluster, plays a critical role in long-chain polyunsaturated fatty acid metabolism by catalyzing the delta-5 desaturase reaction, which converts eicosatrienoyl-CoA (C20:3) to arachidonyl-CoA (C20:4).^[1] This enzymatic step is fundamental for the synthesis of various phospholipids, including glycerol-phosphatidylcholines like PC aa C36:3 and PC aa C36:4, and its efficiency can be significantly altered by genetic polymorphisms. ^[1]

Beyond lipid metabolism, amino acid and uric acid pathways demonstrate precise flux control. ThePARK2gene, encoding parkin, a ubiquitin ligase, influences the concentrations of several amino acids, some of which are directly involved in the urea cycle, indicating its role in amino acid interconversion and degradation.^[1]In uric acid metabolism, theSLC2A9 gene (also known as GLUT9) is a crucial renal urate anion exchanger, and its genetic variants are strongly associated with serum uric acid levels, thereby regulating uric acid homeostasis.^[12] These examples highlight how specific genes and enzymes precisely control metabolic flux through various pathways, impacting the overall physiological state.

Gene Expression and Post-Translational Dynamics

Regulation of gene expression and protein function occurs at multiple levels, from transcription to post-translational modifications. Alternative splicing is a prominent mechanism, where distinct mRNA isoforms are generated from a single gene, leading to proteins with altered functions or expression levels. ^[13] For instance, common SNPs in HMGCR can affect the alternative splicing of its exon 13, consequently influencing the expression and activity of this crucial enzyme in cholesterol synthesis. ^[11] This type of regulation can have a significant impact on metabolic pathways and overall cellular processes.

Protein stability and activity are further controlled by post-translational modifications and degradation pathways. The ubiquitin-proteasome system, exemplified by the PARK2 gene product parkin, a ubiquitin ligase, marks proteins for degradation, a process vital for removing misfolded or superfluous proteins and regulating cellular processes. ^[1] The degradation rate of enzymes like HMG-CoA reductase is also influenced by their oligomerization state, demonstrating another layer of post-translational control over protein abundance and function. ^[14] These regulatory layers ensure precise control over protein repertoire and activity, adapting cellular responses to changing environmental or physiological demands.

Intracellular Signaling and Receptor Interactions

Intracellular signaling cascades mediate cellular responses to external stimuli and internal cues, often initiated by receptor activation. The interaction of proteins with receptors, such as the thyroid hormone receptor, can be precisely regulated, with distinct protein classes binding depending on the presence or absence of the hormone.^[15] This exemplifies how ligand binding to receptors can trigger specific downstream events and transcriptional programs. Furthermore, the human tribbles protein family plays a role in controlling mitogen-activated protein kinase (MAPK) cascades . MAPK pathways are central intracellular signaling networks involved in diverse cellular processes, including growth, proliferation, differentiation, and stress responses, illustrating complex signal transduction.

Transcription factor regulation is another critical component of signaling, where proteins like SREBP-2 (Sterol Regulatory Element-Binding Protein 2) modulate gene expression in response to metabolic signals. ^[16] SREBP-2 specifically regulates genes involved in isoprenoid and adenosylcobalamin metabolism, linking cellular nutrient status directly to transcriptional output. These signaling pathways, encompassing receptor activation, intricate cascades, and transcription factor activity, enable cells to integrate information and mount appropriate physiological responses.

Systems-Level Integration and Network Crosstalk

Biological systems operate through highly integrated networks where individual pathways are interconnected and exhibit crosstalk, leading to emergent properties. Metabolomics, the comprehensive measurement of endogenous metabolites, provides a functional readout of the physiological state and reveals how genetic variants influence the homeostasis of key lipids, carbohydrates, and amino acids. ^[1] Analyzing ratios of metabolite concentrations can significantly reduce data variation and pinpoint specific enzymatic reactions or metabolic pathways affected by genetic polymorphisms, offering deeper insights into network interactions. ^[1] This approach has been particularly effective in identifying the impact of variants in genes like FADS1 on the efficiency of the delta-5 desaturase reaction.

Pathway crosstalk is evident in the regulation of isoprenoid and adenosylcobalamin metabolism by SREBP-2, suggesting a coordinated control mechanism between seemingly distinct metabolic branches. ^[16] Similarly, the influence of PARK2on amino acid concentrations, including those in the urea cycle, highlights the intricate connections between protein degradation and amino acid recycling.^[1] These interactions form a hierarchical regulatory system, where genetic variations at one level can propagate effects across multiple pathways, ultimately shaping complex biological phenotypes.

Dysregulation in Disease and Therapeutic Implications

Dysregulation within metabolic and signaling pathways is a fundamental cause of many human diseases, making these pathways crucial therapeutic targets. Genetic variants impacting HMGCRactivity and alternative splicing, leading to altered LDL-cholesterol levels, are directly implicated in cardiovascular disease risk.^[11] Similarly, genes like ANGPTL3 and ANGPTL4influence lipid concentrations and contribute to the risk of coronary artery disease, highlighting the importance of lipid metabolism in disease pathogenesis.^[17]

Neurodegenerative conditions, such as Parkinson’s disease, can arise from dysfunctions in protein quality control pathways; for instance, loss-of-function mutations inPARK2 (parkin), a ubiquitin ligase, are a known cause. ^[1] Furthermore, metabolic disorders like medium-chain acyl-CoA dehydrogenase deficiency are linked to specific ACADM genotypes. ^[18] Understanding these precise molecular mechanisms, including how variants in genes like SLC2A9affect uric acid levels or howSAMM50 variants lead to mitochondrial dysfunction, can identify critical points for intervention, paving the way for targeted therapies and personalized medicine. ^[12]

Clinical Relevance

Genetic Insights into Disease Risk and Prognosis

Genetic studies provide critical insights into identifying individuals at elevated risk for various conditions, predicting disease progression, and informing personalized prevention strategies. For instance, specific alleles such as theGCKR P446L allele (rs1260326 ) are associated with increased concentrations of APOC-III, an inhibitor of triglyceride catabolism, suggesting a genetic predisposition to dyslipidemia.^[19] Similarly, the LPA coding SNP rs3798220 shows strong associations with LDL cholesterol and lipoprotein(a) levels, which are significant risk factors for cardiovascular disease, enabling improved cardiovascular risk stratification.^[19] Furthermore, genetic risk scores incorporating SNPs in genes like SLC2A9, ABCG2, and SLC17A3can identify individuals at higher risk for hyperuricemia and gout, allowing for targeted preventative measures and personalized management plans based on genetic predisposition.^[20]

Polymorphisms in HNF1Ahave been associated with C-reactive protein (CRP) levels, and other genetic variants inLEPR, LEF1, and IL6R also influence CRP, providing prognostic value for inflammatory conditions. ^[21]These genetic markers can help predict an individual’s inflammatory status and potential long-term implications for diseases where chronic inflammation plays a role. Understanding these genetic influences allows for more precise risk assessment and the development of personalized medicine approaches aimed at preventing disease onset or mitigating its progression. This is particularly relevant when considering the utility of averaging multiple measures of phenotypes over time, which can enhance the detection of true genetic signals.^[21]

Diagnostic and Monitoring Applications

Genetic findings offer substantial utility in diagnostic screening, guiding therapeutic choices, and establishing effective monitoring strategies for patient care. For example, common SNPs in HMGCR are associated with LDL-cholesterol levels and affect the alternative splicing of exon13, providing mechanistic insights into dyslipidemia. ^[11] These genetic insights can inform treatment selection, particularly regarding the efficacy of statin therapies, which target the HMGCR pathway, thereby optimizing patient response to lipid-lowering interventions. ^[11]

Genome-wide association studies (GWAS) on metabolite profiles in human serum have identified genetic variants, such asrs174548 near FADS1, that are linked to concentrations of various phosphatidylcholines and arachidonic acid.^[1]These associations suggest potential for diagnostic biomarkers that could identify specific metabolic imbalances and guide tailored nutritional or pharmacological interventions. Additionally, the identification of genetic loci influencing plasma levels of liver enzymes, as well as associations with other biomarker traits like brain natriuretic peptide and Vitamin K undercarboxylated osteocalcin, provides avenues for early diagnostic screening and ongoing monitoring of organ health and disease progression.^[8]Such genetic markers can help clinicians track disease activity or assess treatment effectiveness, leading to more responsive and individualized patient management.

Comorbidities and Overlapping Metabolic Phenotypes

Genetic research frequently uncovers interconnected biological processes, revealing overlapping phenotypes and shared genetic architectures that contribute to various comorbidities. The polygenic nature of dyslipidemia, for instance, where multiple genetic loci contribute to variations in lipid and lipoprotein profiles, underscores its association with broader cardiovascular risk factors and metabolic syndrome.^[19] Understanding these widespread genetic influences can help in comprehensive patient assessment, especially when managing conditions with shared underlying mechanisms.

Moreover, genetic variants impacting metabolite profiles, such as those involving sphingomyelins through thePLEK gene (rs9309413 ) or amino acid interconversions influenced by thePARK2 gene, can highlight systemic metabolic disruptions. ^[1]These findings are crucial for identifying individuals susceptible to complex comorbidities, as disturbances in one metabolic pathway often have cascading effects on others. The recognition of such overlapping metabolic phenotypes can lead to more holistic patient management strategies, addressing the root causes of multiple conditions rather than isolated symptoms. The interplay between genetic predispositions and environmental factors, as seen in the gene-by-environment interactions influencing uric acid levels and gout risk, further emphasizes the complex etiology of metabolic diseases and the need for integrated prevention and treatment approaches.^[20]

References

[1] Gieger C, et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.” PLoS Genet. 2008 Nov 28;4(11):e1000282. PMID: 19043545.

[2] Vasan, RS et al. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Med Genet, vol. 8, 2007, p. 66.

[3] Yang, Q et al. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.”BMC Med Genet, vol. 8, 2007, p. 64.

[4] Benyamin, B et al. “Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels.”Am J Hum Genet, vol. 84, no. 1, 2009, pp. 60–65.

[5] Benjamin, E. J. et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Med Genet, vol. 8, 2007, p. 56.

[6] Melzer D, et al. “A genome-wide association study identifies protein quantitative trait loci (pQTLs).” PLoS Genet, 2008.

[7] Pare G, et al. “Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women.” PLoS Genet, 2008.

[8] Yuan, X et al. “Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.” Am J Hum Genet, vol. 83, no. 4, 2008, pp. 520–528.

[9] Sabatti, C. et al. “Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.” Nat Genet, vol. 40, no. 12, 2008, pp. 1436-42.

[10] Goldstein, JL, and MS Brown. “Regulation of the mevalonate pathway.” Nature, 1990.

[11] Burkhardt, R. et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol, vol. 28, no. 10, 2008, pp. 1858-65.

[12] Li, S., et al. “The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts.”PLoS Genet, 2007.

[13] Johnson, JM, et al. “Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays.” Science, 2003.

[14] Cheng, HH, et al. “Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase.” J Biol Chem, 1999.

[15] Lee, J.W., et al. “Two classes of proteins dependent on either the pres- ence or absence of thyroid hormone for interaction with the thyroid hormone receptor.”Mol Endocrinol, 1995.

[16] Murphy, C., et al. “Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism.” Biochem Biophys Res Commun, 2007.

[17] Willer, CJ, et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nat Genet, 2008.

[18] Maier, EM, et al. “Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency.” Hum Mutat, 2005.

[19] Kathiresan, S. et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, vol. 40, no. 12, 2008, pp. 1426-35.

[20] Dehghan, A et al. “Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.”Lancet, vol. 372, no. 9654, 2008, pp. 1959–1965.

[21] Reiner, A. P. et al. “Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein.” Am J Hum Genet, vol. 82, no. 5, 2008, pp. 1193-201.